Chapter 31.Asenapine
Sections
Excerpt
Asenapine as a sublingual tablet was initially approved by the U.S. Food and Drug Administration (FDA) in August 2009 for the treatment of acute schizophrenia and acute manic or mixed episodes associated with bipolar I disorder in adults. It was subsequently approved for maintenance treatment of schizophrenia in adults, for adjunctive use with lithium or valproate in the treatment of acute manic or mixed episodes associated with bipolar I disorder in adults, and for bipolar mania in pediatric patients (ages 10–17 years) as a monotherapy (Actavis 2015). In addition to the original unflavored formulation, a black cherry–flavored version of asenapine was brought to the U.S. market in 2010.
Access content
To read the fulltext, please use one of the options below to sign in or purchase access.- Personal login
- Institutional Login
- Sign in via OpenAthens
- Register for access
-
Please login/register if you wish to pair your device and check access availability.
Not a subscriber?
PsychiatryOnline subscription options offer access to the DSM-5 library, books, journals, CME, and patient resources. This all-in-one virtual library provides psychiatrists and mental health professionals with key resources for diagnosis, treatment, research, and professional development.
Need more help? PsychiatryOnline Customer Service may be reached by emailing [email protected] or by calling 800-368-5777 (in the U.S.) or 703-907-7322 (outside the U.S.).
